Table 2. 1L treatment of patients with ROS1 positive NSCLC.

1L treatment for metastatic disease	n = 68 (%)
A. ROS1 TKI	38 (55.88%)
1. Upfront ROS1 TKI a. Crizotinib b. Entrectinib c. Ceritinib 2. Chemotherapy followed by ROS1 TKI 3. Chemo-immunotherapy followed by ROS1 TKI 4. Chemo-bevacizumab followed by ROS1 TKI 5. EGFR TKI + ROS1 TKI	12 (17.65%) 9 (13.24%) 1 (1.47%) 2 (2.94%) 21 (30.88%) 3(4.41%) 1 (1.47%) 1 (1.47%)
B. Other than ROS1 TKI	30 (44.12%)
1. Chemotherapy only (Pemetrexed-carboplatin) 2. Chemo-bevacizumab 3. EGFR TKI 4. No treatment	20 (29.41%) 1 (1.47%) 8 (11.76%) 1 (1.47%)